ILK, integrin linked kinase, 3611

N. diseases: 192; N. variants: 0
Disease: Tumor Progression ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0178874
Disease: Tumor Progression
Tumor Progression 		0.100 Biomarker phenotype BEFREE Alteration in the ILK is responsible for abnormal functioning of the cell system, which may lead to the cancer progression and metastasis. 30488773 2019
CUI: C0178874
Disease: Tumor Progression
Tumor Progression 		0.100 Biomarker phenotype BEFREE ILK is considered as potential drug target because it's direct involvement in the tumor progression. 30227205 2019
CUI: C0178874
Disease: Tumor Progression
Tumor Progression 		0.100 Biomarker phenotype BEFREE Recent research has demonstrated that integrin-linked kinase (ILK), β-parvin and downstream cofilin 1 jointly affected cancer progression. 30250560 2018
CUI: C0178874
Disease: Tumor Progression
Tumor Progression 		0.100 AlteredExpression phenotype BEFREE ILK overexpression in human CRC associates with EMT and CSC traits, contributing to tumor progression and chemoresistance. 29496692 2018
CUI: C0178874
Disease: Tumor Progression
Tumor Progression 		0.100 AlteredExpression phenotype BEFREE Integrin-linked kinase (ILK), a ubiquitously expressed intracellular Ser/Thr protein kinase, plays a major role in the oncogenesis and tumour progression. 29309873 2018
CUI: C0178874
Disease: Tumor Progression
Tumor Progression 		0.100 Biomarker phenotype BEFREE We investigated the role of ILK on cancer progression and metastasis and the therapeutic potential of ILK inhibition in RCC. 25657336 2015
CUI: C0178874
Disease: Tumor Progression
Tumor Progression 		0.100 Biomarker phenotype BEFREE LIMD2 is a small LIM-only protein overexpressed in metastatic lesions that regulates cell motility and tumor progression by directly binding to and activating the integrin-linked kinase. 24590809 2014
CUI: C0178874
Disease: Tumor Progression
Tumor Progression 		0.100 Biomarker phenotype BEFREE Thus, we hypothesize that ILK might bestow growth advantage and metastatic potential in the course of tumor progression. 23840605 2013
CUI: C0178874
Disease: Tumor Progression
Tumor Progression 		0.100 AlteredExpression phenotype BEFREE Taken together, our data suggest that ILK overexpression is associated with tumor progression and a poor prognosis in CRC patients and may represent a novel potential prognostic marker for patients with CRC. 23108908 2013
CUI: C0178874
Disease: Tumor Progression
Tumor Progression 		0.100 AlteredExpression phenotype BEFREE Expression of integrin-linked kinase in adenoid cystic carcinoma of salivary glands correlates with epithelial-mesenchymal transition markers and tumor progression. 23729269 2013
CUI: C0178874
Disease: Tumor Progression
Tumor Progression 		0.100 Biomarker phenotype BEFREE Our results suggest that the novel c-Src-miR-542-3p-ILK-FAK circuit plays a crucial role in controlling tumor progression. 21860426 2012
CUI: C0178874
Disease: Tumor Progression
Tumor Progression 		0.100 Biomarker phenotype BEFREE ILK may be a new molecular target to suppress tumor progression in advanced and high-risk bladder cancer patients. 21351095 2012
CUI: C0178874
Disease: Tumor Progression
Tumor Progression 		0.100 AlteredExpression phenotype BEFREE The overall ILK expression level was significantly higher in tumorous tissues (P = 0.004), with a significant stepwise increase in expression level along tumor progression from tumor stage I to IV (P = 0.045). 21347395 2011
CUI: C0178874
Disease: Tumor Progression
Tumor Progression 		0.100 AlteredExpression phenotype BEFREE Validating the use of a luciferase labeled breast cancer cell line, MDA435LCC6, as a means to monitor tumor progression and to assess the therapeutic activity of an established anticancer drug, docetaxel (Dt) alone or in combination with the ILK inhibitor, QLT0267. 21358264 2011